Sequences facilitating penetration of a substance of interest

Details Sequences facilitating penetration of a substance of interest Sequences facilitating penetration of a substance of interest

2004-08-13

2009-06-09

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S326000

Reexamination Certificate

active

07544664

ABSTRACT:
The present invention relates to an amino acid sequence being able to facilitate penetration of a substance of interest inside cells and/or cell nuclei and having the following formula (I) [(X1)p[(X)o(B)nX B X X B]m(X2)qwherein X1and X2are amino acid sequences of 1 to 20 amino acids; p and q are whole numbers between 0 and 5; B is a basic amino acid; X is a non-basic, preferably hydrophobic amino acid, such as alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, valine or tyrosine; n is 2 or 3; m is 1 to 4; o is 0 or 1, between 0 and 5; B is a basic amino acid; X is a non-basic, preferably hydrophobic amino acid, such as alanine, isoleucine, leucine, methionine phenylalanine, tryptophan, valine or tyrosine; n is 2 or 3; m is 1 to 4; o is 0 or 1.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4526888 (1985-07-01), Williams et al.
patent: 5262564 (1993-11-01), Kun et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5547929 (1996-08-01), Anderson et al.
patent: 5624894 (1997-04-01), Bodor
patent: 5635383 (1997-06-01), Wu et al.
patent: 6043339 (2000-03-01), Lin et al.
patent: 6066485 (2000-05-01), Guthridge et al.
patent: 6274712 (2001-08-01), Springer et al.
patent: 6750321 (2004-06-01), Chen et al.
patent: 6835536 (2004-12-01), Krieger et al.
patent: 6855801 (2005-02-01), San Antonio et al.
patent: 7049286 (2006-05-01), Tchelingerian
patent: 7112562 (2006-09-01), Tchelingerian
patent: 2003/0153490 (2003-08-01), Tchelingerian
patent: 2003/0199677 (2003-10-01), Avrameas et al.
patent: 2004/0123343 (2004-06-01), La Rosa et al.
patent: 2006/0281897 (2006-12-01), Trouet et al.
patent: 2007/0042492 (2007-02-01), Avrameas
patent: 2007/0259813 (2007-11-01), Arranz
patent: WO 90/12587 (1990-11-01), None
patent: WO 91/04315 (1991-04-01), None
patent: WO 94/28921 (1994-12-01), None
patent: WO 96/06632 (1996-03-01), None
patent: WO 96/08274 (1996-03-01), None
patent: WO 96/38163 (1996-12-01), None
patent: WO 97/02840 (1997-01-01), None
patent: WO 98/40401 (1998-09-01), None
patent: WO 98/56938 (1998-12-01), None
patent: WO 99/06632 (1999-02-01), None
patent: WO 99/07414 (1999-02-01), None
patent: WO 99/32136 (1999-07-01), None
patent: WO 99/67284 (1999-12-01), None
patent: WO 00/45831 (2000-08-01), None
patent: WO 01/64738 (2001-09-01), None
patent: WO 03/018636 (2003-03-01), None
patent: WO 03/092736 (2003-11-01), None
patent: WO 03/106491 (2003-12-01), None
patent: WO 2004/011033 (2004-02-01), None
patent: WO 2005/016960 (2005-02-01), None
Seq ID No. 178781 from PG Pub 2004/0123343.
Avrameas, “Efficient Gene Delivery by a Peptide Derived from a Monoclonal anti-DNA Antibody,” Bioconjugate Chem., 1999, 10, pp. 87-93.
Bernfield, “Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans,” Annu. Rev. Cell Biol., 8:365-393 (1992).
Bosanquet, “Chlorambucil: stability of solutions during preparation and storage,” Cancer Chemother. Pharmacol., 18:176 (1986).
Cardin, “Molecular modeling of protein-glycosaminoglycan interactions,” Arterioscler. Thromb. Vasc. Biol. 1989; 9; pp. 21-32.
Darveau, “Beta-Lactam Antibiotics potentiate Magainin 2 Antimicrobial Activity In Vitro and In Vivo,” Antimicrobial Agents and Chemotherapy, American Society for Microbiology, vol. 35, No. 6, 1991, pp. 1153-1159.
David, “Integral membrane heparan sulfate proteoglycans,” 7:1023, 1993.
Esko, “Animal cell mutant in glycosaminoglycan biosynthesis,” Proc. Natl. Acad. Sci., vol. 82, pp. 3197-3201, 1985.
Gueritte, “Relationships between the Structure of Taxol Analogues and Their Atnimitotic Activity,” J. Med. Chem., 34, 1991, pp. 992-996.
Morrow, “Coordinated Action of Glutathione S-Transferases (GSTs) and Multidrug Resistance Protein 1 (MRP1) in Antineoplastic Drug Detoxification,” J. Biol. Chem., vol. 273, No. 32, pp. 20114-20120, 1998.
Niidome, “Chain Length of Cationic alpha-Helical Peptide Sufficient for Gene Delivery into Cells,” Bioconjugate Chemistry, vol. 10, No. 5, 1999, pp. 773-780.
Nogales, “A structure view of microtubule dynamics,” Cell. Mol. Life Sci., vol. 56, 1999, pp. 133-142.
Park, “Mechanism of Action of the Antimicrobial Peptide Buforin II: Buforin II Kills Microorganisms by Penetrating the Cell Membrane and Inhibiting Cellular Functions,” Biochem. Biophys. Res. Commun., 244, pp. 253-257, 1998.
Rostand, “Microbial Adherence to and Invasion Through Proteoglycans,” Infection and Immunity, pp. 1-8, 1997.
Silber, “Chemosensitivity of Lymphocytes From Patients With B-Cell Chronic Lymphocytic Leukemia to Chlorambucil Fludarabine, and Camptothecin Analogs,” Blood, 84:3440, 1994.
Tabosa, “In-vitro and In-vivo evaluation of a new amphotericin B emulsion-based delivery sysytem,” J. Antimicrob. Vhemother., 38, pp. 485-497, 1996.
Travis, “Risk of Leukemia Following Treatment for Non-Hodgkin's Lymphoma,” J. Natl. Cancer Inst., 86:1450, 1994.
Wall, “Camptothecin and Taxol: Discovery to Clinic—Thirteenth Bruce F. Cain Memorial Award Lecture,” Cancer Res., 55:753, 1995.
Zunino, “Molecular mechanisms of resistance to taxanes and therapeutic implications,” Drug Resist. Updat., 2:351, 1999.
International Search Report for International Application No. PCT/IB2004/002936. mailed Oct. 2, 2005.
French Search Report for French Patent Application No. FR0309962 mailed Mar. 10, 2004.
Partial European Search Report for European Patent Application No. EP 03292030 mailed Mar. 1, 2004.
Written Opinion for International Application No. PCT/IB2004/002936.
International Preliminary Report on Patentability for International Application No. PCT/IB2004/002936, issued Feb. 21, 2006.
Accession No. 600165A (Jul. 10, 1992) Insulin.
Accession No. 550085A (Jul. 10, 1992) Insulin.
Accession No. AAH05255 (Jun. 23, 2006) Insulin [Homo sapiens].
Accession No. AAA59179 (Jan. 6, 1995) Insulin [Homo sapiens].
Accession No. AAW99570 (Feb. 14, 2005) Sequence 35 from U.S. Patent No. 6,835,536.
Amara, et al. (1999) Journal of Biological Chemistry 274: 23916-23925.
Arkonac, et al. (1998) Journal of Biological Chemistry 273: 4400-4405.
Avrameas, et al. (1998) Proc. Natl. Acad. Sci. 95: 5601-5606.
Caldwell, et al. (1996) Int. J. Biochem. Cell Biol. 28: 203-216.
Campanelli, et al. (1996) Development 122: 1663-1672.
Cardin, et al. (1988) Biochem. Biophys. Res. Com. 154: 741-745.
Castellot, et al. (May 1986) J. Cell Biol. 102: 1979-1984.
Dini, et al. (1996) Cellular and Molécular Biology 42(2): 269-277.
Fowlkes, et al. (1997) Endocrinol 138: 2280-2285.
Fromm, et al. (1997) Arch. Biochem. Biophys. 343(1): 92-100.
Grieb, et al. (1998) Biochem. Biophys. Res. Comm. 246: 182-191.
Guevara, et al. (1999) Journal of Protein Chemistry 18(8): 845-857.
Hasan, et al. (1999) J. Immunol. 162: 1064-1070.
Hirabayashi, et al. (1993) Scand. J. Immunol. 37: 533-540.
Hirsch (1991) New Engl. J. Med. 324:1565.
Inoue, et al. (1990) FEBS 269: 89-92.
Javadpour, et al. (1996) J. Med. Chem. 39: 3107-3113.
Kallunski & Tryggvason (Jan. 1992) The Journal of Cell Biology 116(2): 559-571.
Kalsi, et al. (1995) Lupus 4: 375-389.
Lookene, et al. (2000) Biochemistry 39: 230-236.
Lortat-Jacob & Grimaud (1991) FEBS 280: 152-154.
Maher, et al. (1989) Mol. Cell Biol. 9: 2251-2253.
Margalit, et al. (1993) Journal of Biological Chemistry 265(26): 19228-19231.
Mesri, et al. (1994) Journal of Cell Science 107 : 2599-2606.
Ngo, et al. (1995)The Protein Folding Problem and Tertiary Structure Predictionpp. 491-495.
Ohta, et al. (Apr. 1994) Free Radical Biology & Medicine 16(4): 501-507.
Olofsson, et al. (1999) Journal of Clinical Investigation.
Pasqualini, et al. (1997) Nature Biotech. 15: 542-546.
Pohl, et al. (1990) FEBS 272: 200-204.
Robinson (1963) Adv. Lip. Res. 1:1 133-182.
Ruoslahti & Yamazuchi (Mar. 1991) Cell 64: 867-869.
Salmivira & Jalkanen (1995) Experentia 51: 863-872.
Stevenson, et al. (1993) J. Autoimmunity 6: 809-825.
Stoll, et al. Journal of Co

Affiliated with

Also associated with

Rating

Sequences facilitating penetration of a substance of interest does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sequences facilitating penetration of a substance of interest, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sequences facilitating penetration of a substance of interest will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4088546